Abstract
The clinical efficacy of intratumoral (IT) OK-432 immunotherapy in advanced cancer patients was investigated. Furthermore, the infiltration of lymphocyte subsets into the tumor tissues after the IT administration of OK-432 was also immunohistologically examined in order to analyze the mechanism of action of OK-432 immunotherapy. Forty-four patients with advanced cancer were treated with IT OK-432 immunotherapy. Ten KE (1 mg) of OK-432 was given either daily or on every second day and repeated as often as possible, the mean frequency of OK-432 injections being 18.1±14.5 times, ranging between 5 and 25 administrations. Thirty-one of the 44 patients were evaluable, 3 of whom (9.7 per cent) developed a partial response and 5 (16.1 per cent) a minor response. Intratumoral OK-432 immunotherapy, however, did not necessarily prolong the survival time. Leu 1, 3 and 7 reactive cells infiltrated into the tumor tissues treated by OK-432 injection, more frequently, when compared with cells which had been treated by recombinant TNF injection. Thus, it was suggested that IT OK-432 immunotherapy might be effective for the local control of tumor growth through the host mediated action, and that, in combination with systemic therapy, may enhance the clinical effects and prolong the survival time in advanced cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Uchida A, Hoshino T. Clinical studies on cell mediated immunity in patients with malignant disease. I Effects of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsivenessin vitro. Cancer 1980; 45: 476–483.
Katano M, Torisu M. Neutrophil mediated tumor cell destruction in cancer ascites. Cancer 1982; 50: 62–68.
Toge T, Yamada H, Aratani K, Kameda A, Kuroi K, Hisamatsu K, Hattori T. Effects of intraperitoneal administration of OK-432 for patients with advanced cancer. Jpn J Surg 1985; 15: 260–265.
Ohmori Y, Honda I, Takahashi H, Michigami J, Kohriyama H, Tanaka Y, Kurokawa S. Intratumoral OK-432 administration in locally advanced breast cancer. Gan to Kagaku Ryoho (Jpn J Cancer Chemother) 1980; 7: 283–292. (in Japanese)
Koyama Y, Saito T. A standard for the evaluation of clinical effects of chemotherapy against solid tumors. Nippon Gan Chiryo Gakkai Zasshi (J Jpn Soc Cancer Ther) 1986; 21: 929–942. (in Japanese)
Hsu SM, Raine L, Fargen H. A comparative study of the peroxidase antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 1981; 75: 734–738.
Watanabe Y, Iwa T. Clinical value of immunotherapy for lung cancer by the streptococcal preparation, OK-432. Cancer 1984; 53: 248–253.
Uchida A, Micksche M. Intrapleural administration of OK-432 in cancer patients: Activation of NK cells and reduction of suppressor cells. Int J Cancer 1983; 31: 1–5.
Imaoka S, Sasaki Y, Matsui Y, Ishikawa O, Taniguchi K, Iwanaga T, Terashima T. Evaluation of intratumoral injection of an immunopotentiator (OK-432) in patients with hepatocellular carcinoma. Nippon Gan Chiryo Gakkai Zasshi (J Jpn Soc Cancer Ther) 1982; 17: 1957–1962. (in Japanese)
Micksche M, Kokoschka EM, Luger T. Experimental and clinical studies with OK-432, a streptococcal preparation with immunomodulation properties. In: Serrou B, ed. Human cancer immunology. Amsterdam: Elsevier/North Holland, Amsterdam, 1982; 31–54.
Sakurai Y, Tsukagoshi S, Satoh H, Akiba T, Suzuki S, Takagaki Y. Tumor inhibitory effects of streptococcal preparation (NSC-B116209). Cancer Chemother Rep 1972; 56: 9–17.
Akura Y, Tanaka N, Kobayashi G, Gotoh K, Gouchi A, Kamitani S, Gangi J, Orita K. The effects of intratumoral OK-432 injection in gastric cancer patients. In: Tobe T, ed. New application of OK-432. Tokyo: Exerpta Medica, 1986; 75–86.
Vanky F, Uchida A, Klein E, Sjovall K, Csemiczky G, Book K, Peterffy A, Willems J, Gunven J. Effect of the streptococcal preparation OK-432 on the lymphocyte mediated lysis of fresh autologous tumor cell. In: Hoshino T, ed. Immunopharmacological aspects of OK-432 in humans. Tokyo: Excerpta Medica, 1986; 1–9.
Watanabe S, Kagawa K, Shira M, Nishioka M. Intratumoral injection therapy in patients with hepatocellular carcinoma. Gan to Kagaku Ryoho (Jpn J Cancer Chemother) 1986; 13: 1635–1641. (in Japanese)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Toge, T., Kuninobu, H., Yamaguchi, Y. et al. The clinical efficacy of intratumoral OK-432 administration in advanced cancer patients. The Japanese Journal of Surgery 18, 668–674 (1988). https://doi.org/10.1007/BF02471528
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02471528